Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S05179 single-pill quadruple therapy versus free triple combination in uncontrolled essential hypertension
2020-004891-16Phase 3Completed
- Sponsor
- Servier
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of S05179, perindopril, indapamide, amlodipine and bisoprolol in essential hypertension (2 arms), sponsored by Servier. Primary endpoint: Office sitting systolic blood pressure. Started Sep 2021; status: completed.
02
Drugs
S05179perindoprilindapamideamlodipinebisoprolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2020-004891-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004891-16.